Abstract: The invention describes recombinant DNA sequences transcribed into RNA constructs capable of forming pseudoknots and being encapsidated in Virus Like Particles having higher insect control efficacy than previously described RNA molecules.

Abstract: The present invention relates to RNAi molecules, and compositions thereof, comprising a 2? internucleoside linkage connecting the nucleotide at position 1 and the nucleotide at position 2 at the 5? end of the antisense strand. Specifically, the invention relates to single- and double-stranded short interfering nucleic acid (siNA) molecules that are capable of mediating RNA interference comprising 5? modified nucleotides that comprise, among other potential modifications, a 2? internucleoside linkage. The invention further relates to 5? modified nucleotides used as reagents to generate the RNAi molecules of the invention and methods of using the disclosed RNAi molecules.

Abstract: The invention teaches antisense agents and RNA interference agents useful for treating diseases and conditions the treatment of which can benefit from reducing the expression of double homeobox 4 and/or double homeobox 4c, more particularly facioscapulohumeral muscular dystrophy. Further elaborated are methods, uses and further products employing such agents.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.

Abstract: The invention pertains to amphiphilic dendrimers complexed with Bcl3 siRNA. The amphiphilic dendriplexes described herein are biodegradable and exhibit enhanced siRNA delivery. The amphiphilic dendriplexes containing Bcl3 siRNA inhibit cancer cell/tumor growth in vitro and in vivo without toxicity. Accordingly, an embodiment of the invention provides a method of treating a cancer, particularly, nasopharyngeal carcinoma, by administering to a subject in need thereof, a therapeutic amount of amphiphilic dendrimers complexed with Bcl3 siRNA. Pharmaceutical compositions containing the amphiphilic dendrimers complexed with Bcl3 siRNA are also provided.

Abstract: A method for improving a cognitive function in a subject comprising administering to said subject an active agent reducing PKR-like endoplasmic reticulum kinase (PERK) activity is provided.

Abstract: The invention relates to a method for treating and/or preventing a tumor growth, invasion and/or metastasis by inhibiting an overexpression of PD-L1 in the subject via an autocrine loop. The invention found that PD-L1-modulated p21 and VEGF-C expression via the TGF?1/SMAD4 pathway is responsible for the cancer growth, invasion and metastasis.

Abstract: Disclosed herein is Candida parapsilosis CGMCC 9630, the carbonyl reductase expressed by said strain and the encoding gene and amino acid sequence thereof, the recombinant expression vector and recombinant expression transformant containing said gene sequence, and use of whole cells of Candida parapsilosis, carbonyl reductase or corresponding recombinant transformant thereof as catalyst in catalyzing asymmetric reduction of prochiral carbonyl compounds, particularly reduction of 6-carbonyl-8-halogenocaprylate to prepare the synthetic precursor of (R)-?-lipoic acid, (R)-6-hydroxy-8-halogenocaprylate. In comparison to other methods of asymmetric reduction for preparing (R)-6-hydroxy-8-halogenocaprylate, the disclosure has advantages of high substrate concentration, mild reaction conditions, environmental friendship, high yield, and high optical purity of the product, and thus has good prospect in industrial production of (R)-?-?-lipoic acid.

Abstract: The invention discloses a method for improving the extracellular expression level of a foreign protein by means of phospholipase fusion expression. Four proteins, PLA2, MBP, CBD and SUMO, are used as a fusion tag to construct a fusion gene. Compared with an original protein MOH without any fusion tag, the extracellular expression level and enzymatic activity of all the four fusion proteins are increased to some degree. Among them, the fusion protein using PLA2 as the fusion tag has the highest expression level, which is 7.4 times higher than that of the original protein. Compared with other fusion tags, PLA2 has a low molecular weight and the fusion protein having PLA2 as the fusion tag has the highest expression level (up to 12 g·L?1 in a 7 L fermentation tank for high-density fermentation). It is shown that the secretory expression of a foreign protein can be effectively increased by using PLA2 as a fusion tag.

Abstract: The present disclosure comprises methods and compositions comprising a plant transforming bacterium of the Order Rhizobiales comprising conditional negative selectable marker genes.

Abstract: A method of real-time prognosis of a flooding phenomenon in a packed column includes steps as follows. An online data collection step is conducted, wherein a plurality of values of the pressure drop are collected from the packed column under operation. A calculation step is conducted, wherein the values of the pressure drop are used to calculate a plurality of values of a steadiness index. A statistical step is conducted, wherein a value of a monitoring statistic is calculated based on the values of the steadiness index. A control step is conducted, wherein the value of the monitoring statistic is compared to a control limit, and an alarm is triggered when the value of the monitoring statistic is greater than the control limit.

Abstract: The present invention discloses a process for manufacturing a formulation comprising a drug substance, said drug substance comprising a recombinant Listeria comprising a human papilloma virus (HPV) antigen fused to a Listeriolysin O (LLO) protein fragment. The invention further discloses methods of using treating, protecting against, and inducing an immune response against cervical cancer comprising administration of the recombinant Listeria strain. The present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.

Abstract: The invention generally relates to arogenate dehydrogenase polynucleotides and methods of using the same. More specifically, the invention relates in part to compositions including arogenate dehydrogenase polynucleotides from beet varieties and other Caryophyllales species and methods of using the same.

Abstract: The disclosure describes promoter sequences, specifically S-Adenosyl-Homocysteine Hydrolase promoter sequences from maize and sorghum, which are useful for expression of transgenes in plants. The disclosure further describes isolated polynucleotides, recombinant DNA constructs, transformed host cells, transgenic plants and transgenic seeds, and corresponding methods of use of the promoter sequences.

Abstract: The invention relates to genetically modified plants with an altered seed phenotype, in particular increased seed size. The invention relates to a plant that does not produce a functional NGAL2 polypeptide or functional NGAL2 and NGAL3 polypeptides. NGAL2 and NGAL3 are members of the RAV family and comprise a B3 DNA-binding domain and a transcriptional repression motif.

Abstract: A series of independent human-induced non-transgenic mutations found at one or more of the SBEII genes of wheat; wheat plants having these mutations in one or more of their SBEII genes; and a method of creating and finding similar and/or additional mutations of SBEII by screening pooled and/or individual wheat plants. The seeds and flour from the wheat plants of the present invention exhibit an increase in amylose and resistant starch without having the inclusion of foreign nucleic acids in their genomes. Additionally, the wheat plants of the present invention exhibit altered SBEII activity without having the inclusion of foreign nucleic acids in their genomes.

Abstract: A series of independent human-induced non-transgenic mutations found at one or more of the Lpx genes of wheat; wheat plants having these mutations in one or more of their Lpx genes; and a method of creating and finding similar and/or additional mutations of Lpx by screening pooled and/or individual wheat plants. The wheat plants disclosed herein exhibit decreased lipoxygenase activity without having the inclusion of foreign nucleic acids in their genomes. Additionally, products produced from the wheat plants disclosed herein display increased oxidative stability and increased shelf life without having the inclusion of foreign nucleic acids in their genomes.

Abstract: Monoclonal antibodies produced in plants at high levels wherein elimination of L chain glycans improves plasma stability of certain plant derived bnAbs are provided. Monoclonal antibodies produced in plants which exhibit no or reduced immunogenicity after multiple injections are provided. Methods of production of the foregoing are provided. Methods of determining immunogenicity assessing the immunogenicity and neutralizing ability of the same are provided. Methods of treating HIV using monoclonal antibodies produced in plants are also provided.

Abstract: Hypersensitive PYR/PYL polypeptides, compositions, and methods are provided.

Abstract: Ocimum basilicum plants or germplasm having tolerance or improved tolerance to Peronospora belbahrii infection, comprising in its genome the single nucleotide polymorphisms (SNPs) of SEQ ID NOs:1-630 or having approximately 90% to 0.5% of said SNPs in said Ocimum basilicum genome are disclosed.

Abstract: A recombinant BMYV P0 viral nucleotide sequence when transcribed in a cell is capable of forming a double stranded self-complementary RNA sequence.

Abstract: The present invention provides the identification and use of EG261, homologs of EG261, orthologs of EG261, paralogs of EG261, and fragments and variations thereof for altering, e.g. increasing, pathogen tolerance and/or resistance in plants.

Abstract: The invention belongs to the field of molecular biology, and relates to an efficient and safe transposon integration system and use thereof. The invention also relates to a nucleic acid construct and use thereof. Preferably, the nucleic acid construct comprises the following elements in order: a 5?-terminal repeat sequence of a transposon, a multiple cloning site, a polyA tailing signal sequence, a 3?-terminal repeat sequence of a transposon, a sequence encoding a transposase and a promoter controlling expression of the transposase; wherein the multiple cloning site is used for operably inserting an exogenous gene and optionally a promoter controlling expression of the exogenous gene; the polyA tailing signal sequence has a polyA tailing signal function in both forward and reverse directions; and the direction of the expression cassette of the transposase is opposite to the direction of the exogenous gene expression cassette.

Abstract: The invention pertains to an expression vector or a combination of at least two expression vectors comprising at least (a) a polynucleotide encoding a product of interest or an insertion site for incorporating a polynucleotide encoding a product of interest; (b) a polynucleotide encoding a first selectable marker (sm I); (c) a polynucleotide encoding a second selectable marker (sm II), which is different from the first selectable marker (sm I), wherein the activity of the selectable marker (sm I) or (sm II) is at least partially influenced by the activity of the other selectable marker and wherein the selectable markers (sm I) and (sm II) are involved in the folate metabolism. Also provided are suitable host cells, selection methods and methods for producing polypeptides with high yield.

Abstract: The present invention relates to methods and compositions for maggot debridement therapy. More specifically, the invention relates to recombinant nucleic acid constructs, transgenic maggots comprising the recombinant nucleic acids, methods for making the maggots, and methods for the use of the maggots, including debridement and promoting of wound healing.

Abstract: They are provided gene constructs comprising a nucleotide sequence encoding the Insulin-like growth factor 1 (IGF-1) of a mammal; and target sequences of a microRNA of a tissue where the expression of IGF-1 is wanted to be prevented, wherein the sequences (a) and (b) are operationally linked to a promoter of ubiquitous expression. Also provided are expression vectors comprising the gene construct and pharmaceutical compositions comprising them. They are useful in the treatment and/or prevention of diabetes mellitus in mammals, wherein a dysfunction and/or a loss of the beta-cells of the islets of Langerhans is present.

Abstract: Provided is a gene expression cassette for stably and highly producing a protein of interest. The gene expression cassette has a structure in which a DNA construct (X) containing a gene of interest and a poly A addition sequence is sandwiched between a promoter (P) and an enhancer (P?), the gene expression cassette further including transposon sequences (T) upstream of the promoter (P) and downstream of the enhancer (P?). Further, in the gene expression cassette, when a nuclear matrix binding sequence (M) is appropriately arranged upstream of a replication initiation sequence (S) in combination with the transposon sequence (T), the protein of interest can be more effectively produced stably and in a large amount. For example, HRG, PD-1, EMMPRIN, NPTN?, EMB, RAGE, MCAM, ALCAM, ErbB2, and an antibody can each be produced stably and in a large amount.

Abstract: The invention features Cas9 fusion polypeptides. In one embodiment of the invention, Cas9 is fused to a SNAP tag that enhances Cas9's gene repair function.

Abstract: The invention relates to fungal cells for the production of FDCA. The fungal cell is genetically modified to have at least one of a) a genetic modification that confers to or increases in the cell the ability to oxidize 5-hydroxymethyl-2-furancarboxylic acid to 5-formyl-2-furoic acid; and, b) a genetic modification that reduces catabolism of 2,5-furandicarboxylic acid in the cell. The fungal cell can further be genetically modified to increase the cell's ability to oxidize furanic aldehydes to the corresponding furanic carboxylic acids. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) wherein the cells of the invention are used for oxidation of a furanic precursors of FDCA.

Abstract: The invention relates to recombinant microorganisms and methods for producing macrocyclic diterpene or oxidized macrocyclic diterpene.

Abstract: Systems and methods for fixing carbon using bacteria are described. In one embodiment, a system includes a reactor chamber with a solution contained therein. The solution may include hydrogen (H2), carbon dioxide (C02), bioavailable nitrogen, and a chemolithoautotrophic bacteria. The system may also include a pair of electrodes that split water contained within the solution to form the hydrogen. Additionally, the system may be operated so that a concentration of the bioavailable nitrogen in the solution is below a threshold nitrogen concentration to cause the chemolithoautotrophic bacteria to produce a product.

Abstract: According to one embodiment, provided is a carbon dioxide fixation device including a nonaqueous phase and an aqueous phase. The nonaqueous phase includes an ionic liquid, an enzyme body, and a mediator. The enzyme body catalyzes a reduction reaction of carbon dioxide or a reduced product of carbon dioxide. The mediator acts as a reducing agent or coenzyme in this reduction reaction. The nonaqueous phase is configured such that the reduction reaction generates a reaction product. The aqueous phase includes an extraction liquid containing water. The aqueous phase is configured such that the abovementioned reaction product is supplied thereto from the nonaqueous phase.

Abstract: The present invention generally relates to the production of biofuels and, in particular, to a process for simultaneous saccharification and fermentation using a microalgae substrate. According to one aspect of the present invention, a process is provided in which the temperature and pH of a broth mixture are adjusted to slow the rate of glucose conversion and to match the glucose metabolizing rate of the microalgae.

Abstract: The efficient production of ethanol from low-cost biomass (e.g., corn, sugar beets, sugar cane, switchgrass and/or paper) has become increasingly important in making ethanol competitive with gasoline and decreasing the United States' dependence on foreign oil. For example, to reduce the cost of transporting biomass to ethanol production facilities, mobile systems for producing ethanol from biomass are provided. Also provided are small-scale ethanol production facilities. For example, instead of transporting biomass to the production facility, the facility is transported to the biomass or is located nearby the source of the biomass. The ethanol production facilities or components thereof may be transported via land, water, or air. Production of other products, such as hydrocarbons, natural gas, hydrogen gas, plastics, polymers, and proteins, can also be made by the methods and facilities. Any product described herein can be made in finished form or un-finished form and moved, e.g., to a fixed facility, e.g.

Abstract: Provided herein are recombinant host cells having an active 3-Hydroxypropionic Acid (3-HP) pathway wherein the host cells comprise a heterologous polynucleotide encoding an aminotransferase of E.C. 2.6.1.19 and wherein the aminotransferase comprises the motif (A,C)-Xn-(GSLS)-Xn-SKA(L/l)(L/l). Also described are methods of making the host cells, and methods using the cells to produce 3-HP and derivatives of 3-HP (e.g., acrylic acid).

Abstract: The present invention relates to the microbial production of malate. Fungal cells belonging to a species of the family of Ustilaginaceae were found to be an excellent host for the production of malate from glycerol. The malate production rate of fungal cells belonging to a species of the family of Ustilaginaceae was increased significantly by laboratory evolution. After medium optimization, a cultivation with the evolved strain on minimal medium with glycerol, or mono- or disaccharides, like glucose or sucrose or oligosaccharides yields a high production rate of malate.

Abstract: The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.

Abstract: Methods of producing peptide beta-lactones and beta-hydroxy acids are disclosed that include contacting a beta-hydroxy-alpha-amino acid, an aryl carrier protein (ObiD), and ATP with a non-ribosomal protein synthetase. A continuous flow reactor is disclosed that includes an elongate conduit with at least one region that includes a first region with a non-ribosomal protein synthetase immobilized to a substrate. The non-ribosomal protein synthetase of the continuous flow reactor is configured to contact a flow of a reaction mixture that includes a beta-hydroxy-alpha-amino acid and an aryl carrier protein. The non-ribosomal protein synthetase is further configured to release a peptide beta-lactone into the flow of the reaction mixture.

Abstract: A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor. The recombination intermediate is treated with a high fidelity polymerase to permit the replication and amplification of the target nucleic acid sequence. In preferred embodiments, the polymerase comprises a polymerase holoenzyme. In further preferred embodiments, the recombination factor is bacteriophage T4 UvsX protein or homologs from other species, and the polymerase holoenzyme comprises a polymerase enzyme, a clamp protein and a clamp loader protein, derived from viral, bacteriophage, prokaryotic, archaebacterial, or eukaryotic systems.

Abstract: The present invention relates to a method for producing 2-O-glyceryl-?-D-glucopyranoside (?GG; FIG. 1) from a glucosyl donor and a glucosyl acceptor comprising the steps: providing a sucrose phosphorylase (EC 2.4.1.7), incubating said sucrose phosphorylase with a mixture comprising a glucosyl donor and glycerol as glucosyl acceptor and isolating and/or purifying 2-O-glyceryl-?-D-glucopyranoside.

Abstract: The present invention relates to a cell determination method for determining a cell type based on a content of glycogen in a cell, including: an acquisition step of acquiring optical path length data by measuring an optical path length of the cell; a calculation step of calculating an optical path length indicator correlated with the optical path length of the cell from the obtained optical path length data; a comparison step of comparing the calculated optical path length indicator with a threshold; and a determination step of determining whether the cell is a cell type having a high glycogen content in the cell or a cell type having a low glycogen content in the cell, based on the comparison result.

Abstract: The invention relates to methods and instruments for the rapid detection and rapid mass spectrometric identification of microbial infective agents in blood or other body fluids. The invention recognizes that blood is not a good environment for the cultivation of microbes and provides a method which (a) largely destroys or dissolves the human particles in body fluids, such as erythrocytes and leukocytes in blood, without impairing the ability of the microbes to reproduce, (b) separates the microbial pathogens from the fluid, (c) cultivates them in a nutrient broth which contains none of the antimicrobial components of the body fluids, (d) separates them from the nutrient broth, and (e) identifies the microbes by a mass spectrum of the microbial proteins. The dissolution of the human particles also releases the microbes nesting in macrophages.

Abstract: Provided herein is an ?-fucosidase that can cleave a conjugate comprising an N-glycan and a label where the label is added by amine reactive chemistry. The ?-fucosidase also has an accelerated reaction time using Schiff base labeled N-glycans compared with BKF. A reaction mix, enzyme mix and kit comprising the ?-fucosidase are provided, as well as a method for analyzing glycoproteins. The ?-fucosidase finds particular use in analyzing the N-glycans of therapeutic glycoproteins.

Abstract: The present invention is directed to compositions and methods using triptycene derivatives (TCDs) for three way junctions (TWJs).

Abstract: The present invention relates to modified 3? region extraction and deep sequencing of polyadenylated RNA to identify a poly(A) site in a reference, as well as to calculate poly(A) tail length.

Abstract: The invention relates to a method of determining an infection of a patient with Pseudomonas species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Pseudomonas infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Pseudomonas species, as well as computer program products used in these methods. In an exemplary method, a sample 1, is used for molecular testing 2, and then a molecular fingerprint 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine, isolating corresponding mRNA, and analyzing expression patterns in order to diagnose and treat various post-kidney transplant complications. In particular, annexin1 mRNA expression patterns are analyzed through a unique diagnostic formula.

Abstract: Methods and compositions for altering prokaryotic cellular viability phenotypes, including antibiotic susceptibility.

Abstract: We disclose a drug tracking system and method of use which may be used to screen a user's bodily waste and to collect information about the drugs the user has consumed. The system includes mixing or adhering a drug tag with a drug compound. The drug tag includes at least one nucleic acid or nucleic acid analog, the unique nucleotide sequence of which correlates to information about the drug. The unique sequence may correlate with a drug molecule, a drug class, a manufacturer, and/or a distributer. Each of these categories of information may be incorporated into the nucleotide sequence of a separate nucleic acid or nucleic acid analog molecules or combined in a single molecule. The sequence of the drug tag may be entered into a database which stores the drug information associated with each discrete nucleotide sequence.

Abstract: The present invention relates to methods and devices for identifying and quantifying, including low abundance, nucleotide base mutations, insertions, deletions, translocations, splice variants, miRNA variants, alternative transcripts, alternative start sites, alternative coding sequences, alternative non-coding sequences, alternative splicings, exon insertions, exon deletions, intron insertions, or other rearrangement at the genome level and/or methylated nucleotide bases.